We are live on ! Find out more
SL

Siren LLC Portfolio holdings

AUM $3.61B
1-Year Est. Return 203.3%
This Fund
S&P 500
This Quarter Est. Return
+18.65%
1 Year Est. Return
+203.3%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.93B
AUM Growth
+$160M
Cap. Flow
+$578K
Cap. Flow %
0.03%
Top 10 Hldgs %
48.49%
Holding
131
New
15
Increased
21
Reduced
19
Closed
21

Top Buys

Rank Stock Value
1
DYN icon
Dyne Therapeutics
DYN
+$23.3M
2
BCAX
Bicara Therapeutics
BCAX
+$23.2M
3
EWTX icon
Edgewise Therapeutics
EWTX
+$21.1M
4
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$20.7M
5
AVBP icon
ArriVent BioPharma
AVBP
+$14.5M

Top Sells

Rank Stock Value
1
BPMC
Blueprint Medicines
BPMC
+$64.3M
2
SLNO
Soleno Therapeutics
SLNO
+$19.5M
3
PRTA icon
Prothena Corp
PRTA
+$15.9M
4
SMMT icon
Summit Therapeutics
SMMT
+$13.4M
5
NAMS icon
NewAmsterdam Pharma
NAMS
+$13.1M

Sector Composition

Rank Sector Weight
1 Healthcare 90.42%
2 Technology 4.93%
3 Communication Services 2.51%
4 Consumer Discretionary 1.07%
5 Real Estate 0.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SRRK icon
1
Scholar Rock
SRRK
$6.44B
$328M 16.95%
9,250,005
– –
KYMR icon
2
Kymera Therapeutics
KYMR
$8.94B
$150M 7.74%
3,428,150
+187,837
+6% +$6.47M
ONC
3
BeOne Medicines Ltd
ONC
$38.7B
$123M 6.39%
509,990
+11,301
+2% +$2.77M
IRON icon
4
Disc Medicine
IRON
$2.97B
$58.2M 3.01%
1,099,401
+27,536
+3% +$1.29M
CRNX icon
5
Crinetics Pharmaceuticals
CRNX
$8.92B
$48.6M 2.51%
1,688,611
– –
BCAX
6
Bicara Therapeutics
BCAX
$1.84B
$48.5M 2.51%
5,216,969
+1,949,886
+60% +$23.2M
DYN icon
7
Dyne Therapeutics
DYN
$4.9B
$46M 2.38%
4,836,437
+2,118,450
+78% +$23.3M
CNTA
8
DELISTED
Centessa Pharmaceuticals
CNTA
$45.5M 2.35%
3,460,029
+500,000
+17% +$6.33M
MRUS
9
DELISTED
Merus
MRUS
$44.9M 2.32%
853,467
-190,000
-18% -$8.93M
APLS
10
DELISTED
Apellis Pharmaceuticals
APLS
$44.6M 2.31%
2,578,396
– –
ASND icon
11
Ascendis Pharma A/S
ASND
$16.8B
$42.4M 2.2%
245,943
-41,423
-14% -$6.75M
ARWR icon
12
Arrowhead Research
ARWR
$12.4B
$42.2M 2.18%
2,669,880
– –
EWTX icon
13
Edgewise Therapeutics
EWTX
$4.68B
$41.4M 2.14%
3,160,298
+1,463,854
+86% +$21.1M
SLNO
14
DELISTED
Soleno Therapeutics
SLNO
$39.2M 2.03%
467,342
-259,995
-36% -$19.5M
LXRX icon
15
Lexicon Pharmaceuticals
LXRX
$1.1B
$36.8M 1.9%
38,918,903
– –
TBLA icon
16
Taboola.com
TBLA
$1.11B
$36.5M 1.89%
9,969,495
– –
SLDB icon
17
Solid Biosciences
SLDB
$826M
$36.1M 1.87%
7,415,905
– –
RVMD icon
18
Revolution Medicines
RVMD
$44B
$34.5M 1.79%
938,755
+375,000
+67% +$14.4M
RNAM
19
DELISTED
Avidity Biosciences
RNAM
$31.5M 1.63%
1,110,610
– –
RYTM icon
20
Rhythm Pharmaceuticals
RYTM
$7.96B
$25.9M 1.34%
409,742
+132,209
+48% +$8.1M
APGE icon
21
Apogee Therapeutics
APGE
$10.2B
$25.8M 1.34%
594,994
– –
STOK icon
22
Stoke Therapeutics
STOK
$2.11B
$25.5M 1.32%
2,247,347
– –
TSHA icon
23
Taysha Gene Therapies
TSHA
$1.89B
$25.4M 1.32%
11,014,737
+4,500,000
+69% +$9.78M
XENE icon
24
Xenon Pharmaceuticals
XENE
$6.12B
$25.4M 1.32%
812,761
+80,000
+11% +$2.61M
WVE icon
25
Wave Life Sciences
WVE
$1.2B
$24M 1.24%
3,696,322
– –
1
2 3 4 5

Similar funds

SCM
Saba Capital Management New York $3.62B AUM 12.96% 1-Year Est. Return
ACM
Advent Capital Management New York $3.63B AUM 0.29% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $3.63B AUM 30.51% 1-Year Est. Return
VI
Vestcor Inc Fredericton, New Brunswick, Canada $3.63B AUM 21.49% 1-Year Est. Return
BPS
BNDES Participacoes SA Rio De Janeiro, Brazil $3.58B AUM
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
WWA
WCG Wealth Advisors Las Vegas, Nevada $3.57B AUM 18.63% 1-Year Est. Return
OCM
One Capital Management Westlake Village, California $3.65B AUM 15.32% 1-Year Est. Return

Siren LLC's Q2 2025 Portfolio in Review

As of Q2 2025, Siren LLC held 131 positions worth $1.93B, up 9% from $1.77B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Siren LLC's Q2 2025 filing shows 15 new, 21 increased, 19 reduced and 21 closed positions. Its largest new stake was MoonLake Immunotherapeutics: 508,267 shares worth $24M. The largest sale was Blueprint Medicines, an estimated $64.3M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 90% a quarter earlier, followed by Technology and Communication Services.

  • Siren LLC's largest Q2 2025 buy was MoonLake Immunotherapeutics: 508,267 shares worth $24M.
  • Siren LLC added most to Dyne Therapeutics in Q2 2025, an estimated $23.3M increase.
  • Siren LLC's biggest Q2 2025 reduction was Soleno Therapeutics, cutting an estimated $19.5M.
  • Siren LLC fully exited Blueprint Medicines in Q2 2025, selling an estimated $64.3M.
  • Siren LLC's ten largest holdings make up 48% of its $1.93B portfolio in Q2 2025.
  • Siren LLC opened 15 new positions and closed 21 in Q2 2025.
  • Siren LLC's portfolio value rose 9% quarter-over-quarter to $1.93B.

Based on Siren LLC's 13F filing for Q2 2025, filed 13 Aug 2025.